Savara Inc. (SVRA)
$5.56-0.54%Close
SELLRECOVERY · day 2
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $1.1B
- Avg volume
- 1.6M
- Beta
- 0.26
- P/E (TTM)
- -9.64
- Short % float
- 34.46%
- Days to cover
- 20.1
- SI change
- +7.8%
- 1W
- +3.54%
- 1M
- +0.91%
- 3M
- +10.76%
- YTD
- -1.42%
- vs SPY 1W
- +4.73%
- vs SPY 1M
- -2.41%
- vs SPY 3M
- +8.37%
- vs SPY YTD
- -13.17%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- ABVXSELLAbivax S.A.BEARQ 61$116.15+1.04%
- ERASSELLErasca, Inc.RECOVERYQ 6$17.60-0.17%
- MLYSSELLMineralys Therapeutics, Inc.RECOVERYQ 21$25.27-1.48%
- RVMDBUYRevolution Medicines, Inc.BULLQ 31$211.58+1.01%
- ANIXBUYAnixa Biosciences, Inc.RECOVERYQ 6$3.62-2.43%
- ANROBUYAlto Neuroscience, Inc.BULLQ 27$36.25+5.75%
- CTNMBUYContineum Therapeutics, Inc. Class A Common StockRECOVERYQ 13$16.63-3.26%
- SMMTSELLSummit Therapeutics Inc.CRISISQ 16$12.73-3.27%
- EIKNBUYEikon Therapeutics, Inc. Common StockQ -15$11.16-2.02%
- KLRASELLKailera Therapeutics, Inc.Q -44$16.54-3.67%
- FBIOSELLFortress Biotech, Inc.RECOVERYQ -9$2.93+2.09%
- NNNNSELLAnbio Biotechnology Class A Ordinary SharesCRISISQ 24$7.90+16.01%
Industry peers
FMP comparable companies · ranked by market cap
- TNGXSELLTango Therapeutics, Inc.$3.9BCRISISQ 24$23.88+2.64%
- NBTXBUYNanobiotix S.A.$2.2BCRISISQ 23$43.55-8.93%
- GHRSBUYGH Research PLC$1.9BBEARQ 19$28.33-0.81%
- BCAXSELLBicara Therapeutics Inc. Common Stock$1.6BCRISISQ 0$23.90-1.34%
- TYRASELLTyra Biosciences, Inc.$1.6BCRISISQ 9$26.05+0.15%
- KURABUYKura Oncology, Inc.$1.1BRECOVERYQ 13$11.89+4.29%
- GERNBUYGeron Corporation$975MRECOVERYQ 11$1.52+0.00%
- PROKSELLProKidney Corp.$541MRECOVERYQ 0$1.61+0.00%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 8
- GROWTH
- 45
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-54.2%
REV YoY-
ROE-90.3%
EPS YoY-
ROA-72.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-9.64
P/E FWD-
SECTOR PE22.62
INDUSTRY PE17.13
P/B9.87
P/FCF-
EV/EBITDA-8.14
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E20.96
ALTMAN Z-
CURR RATIO10.13
ND/EBITDA-
BETA0.26
